Fig. 5.

SeMet enhances the antitumor activity of DOX. (a) SeMet alone does not affect the viability of H9C2 cells treated with various concentrations of DOX or cisplatin. Cell viability was measured by Cell-Quanti-Blue. H9C2 cells grown with or without 100 nM SeMet supplementation in the growth medium were treated for 24 h, and then cells were treated with DOX for 24 h. (b) Tumor volumes at the indicated times (n = 6–7 females per group). Groups were compared using one-way ANOVA (*P < 0.05; **P < 0.01). DOX (4 mg/kg) was administered to mice via the tail vein on days 0, 7, and 14. SeMet (0.75 mg/kg, by gavage, weekly) was administered before DOX administration and after the start of DOX (0.375 mg/kg, by gavage, weekly). (c) We subjected different concentrations of Se in Se-rich oyster mushrooms to conform effective dosage ranges that can protect against doxorubicin-induced cardiomyopathy. Kaplan‒Meier survival curves of the indicated mice treated with Se-rich oyster mushrooms (counted as SeMet) followed by DOX (20 mg/kg, i.p.) (n = 10 mice per group). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)